On World Cancer Day, Global Good and QuantuMDx have announced a new partnership to develop a rapid, low-cost and mobile diagnostic test that could make a tremendous difference in the global fight against cervical cancer.
Source: Pink Ribbon Red Ribbon
Cervical cancer is almost entirely preventable, yet it kills nearly 270,000 women worldwide every year. Yet, as deaths from the slow-growing disease drop in the U.S., women in the developing world are dying at an unprecedented rate. That’s because many of these women who have human papillomavirus (HPV) – the leading cause of cervical cancer – don’t return to health facilities to receive follow up care. A point-of-care HPV test that provides health workers with immediate results, allowing them to screen and treat women during a single visit, is critical.
Enter QuantuMDx and Global Good, working together to harness the wide-ranging benefits of QuantuMDx’s technology platform including the speed, accessibility and affordability of its battery-operated portable Q-POC™ diagnostic laboratory along with the global health expertise of Global Good, to make gold standard HPV testing accessible to women worldwide.
The new test will be affordably priced, easy to use, and highly accurate. And, as Celina Schocken, CEO of Pink Ribbon Red Ribbon points out in a new post on Medium:
“Cervical cancer is a disease fueled by poverty and poor access to healthcare. It grows slowly, so women with access to regular health care are generally diagnosed before it is too late. Women with HIV are five times more likely to develop the disease, due to their compromised immune systems. And women throughout Africa who have symptoms are afraid to be tested because so little treatment is available… I’m looking forward to seeing this test in action around the world. Women’s lives depend on it.”
To learn more about HPV diagnostics, and how they will be used in developing countries, please read the analysis written by Pink Ribbon Red Ribbon, Investing in Cervical Cancer Screening: A Point of Care Test HPV Diagnostic to Reduce Cervical Cancer Deaths in Developing Countries.
For the full press release of the announcement, click here.